Finance

Lists
Outlook: 58.3% bullish·4.2% bearish
Go to analysis
INO:NASDAQ
Inovio Pharmaceuticals Inc
US$ १.५१
०.००%
(०.००) 1D
US$ १.४८
-१.९९% (-०.०३०)
Pre-market
Closed: नोभेम्बर ९, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Mkt. cap
१५.५५ करोड
Avg. vol.
१.८४ करोड
Volume
१३.०९ लाख
52-wk high
US$ २.७२
52-wk low
US$ ०.५६
EPS
-US$ १.१७
Beta
१.७१
Shares outstanding
१०.३४ करोड
No. of employees
११२
Mkt. cap
१५.५५ करोड
Avg. vol.
१.८४ करोड
Volume
१३.०९ लाख
52-wk high
US$ २.७२
52-wk low
US$ ०.५६
EPS
-US$ १.१७
Beta
१.७१
Shares outstanding
१०.३४ करोड
No. of employees
११२
News stories
From web sources and news partners
Investing.com Canada
Investing.com Canada
·
१ दिन पहिले
Form 8K Inovio Pharmaceuticals Inc For: 9 November By Investing.com
TradingView
TradingView
·
१ दिन पहिले
INO Q3'26 Earnings: EPS estimate is (0.20) USD
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees११२
Founded१९९९
Headquarters-
SectorHealth Care
Industry-
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current US$ १.५१
US$ ८.०० (+४२९.८०%)
Average
US$ ५.६७ (+२७५.५०%)
Lowest
US$ ४.०० (+१६४.९०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Roger Song
Jefferies
Buy
Reiterated
US$ ८.००
+४२९.८%
11/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Upgraded
US$ ५.००
+२३१.१%
11/02/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
US$ ४.००
+१६४.९%
11/02/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
US$ १३.००
+७६०.९%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
१.३३ करोड
१.०३ करोड
१.४१ करोड
१.०८ करोड
Cost of revenue
१.३३ करोड
१.०३ करोड
१.४१ करोड
१.०८ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७८.७७ लाख
७२.१५ लाख
७८.८० लाख
७७.९८ लाख
Operating expense
७८.७७ लाख
७२.१५ लाख
७८.८० लाख
७७.९८ लाख
Total operating expenses
२.१२ करोड
१.७५ करोड
२.१९ करोड
१.८६ करोड
Operating income
-२.१२ करोड
-१.७५ करोड
-२.१९ करोड
-१.८६ करोड
Other non operating income
-२.४३ करोड
२.१२ करोड
४१.३७ लाख
१.२७ करोड
EBT including unusual items
-४.५५ करोड
३७.६५ लाख
-१.९७ करोड
-६०.१२ लाख
EBT excluding unusual items
-४.५५ करोड
३७.५५ लाख
-१.९५ करोड
-५५.३३ लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-४.५५ करोड
३७.६५ लाख
-१.९७ करोड
-६०.१२ लाख
Net profit margin
-
-
-
-
Earnings per share
-०.८७
-०.२८
-०.३१
-०.२४
Interest and investment income
५.५२ लाख
४.४९ लाख
४.४० लाख
३.६४ लाख
Interest expense
-
-
-
-
Net interest expenses
५.५२ लाख
४.४९ लाख
४.४० लाख
३.६४ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.०९ करोड
-१.७१ करोड
-२.१६ करोड
-१.८३ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू